Skip to content

James Chue

3 papers in the library · 24 citations · publishing 2018-2022

Papers

Sort Most recent Most cited

A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms

European Psychiatry June 1, 2022 Pierre Chue, A. Andreiev, E. Bucuci et al. 6 citations

Introduction The 5-HT 2A agonist classic psychedelic, psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a tryptophan, indole-based alkaloid present in up to 2% of certain hallucinogenic “magic” mushroom species; typically Psilocybe azurescens, semilanceata, and cyanescens,. In addition, mushrooms may contain psilocin (4-hydroxy-N,N-dimethyltryptamine). Both are indolylalkylamines...

P.0623 The clinical relevance of the pharmacokinetics of psilocybin

European Neuropsychopharmacology December 1, 2021 A. Andreiev, E. Bucuci, James Chue et al. 1 citation

Nicotine dependence is a reversible risk factor of numerous oral cavity diseases. Dentist should be non-smoking and have knowledge on diagnosis and treatment of nicotine addiction.The aim of this survey is the assessment of prevalence of nicotine dependence among Polish dentists, factors associated with this addiction and knowledge on minimal anti-nicotine intervention acquired during pre- and...

A review of ketamine’s role in ECT and non-ECT settings

Neuropsychiatric Disease and Treatment June 1, 2018 Vytautas Jankauskas, Candace Necyk, James Chue et al. 17 citations

Up to 20% of depressed patients demonstrate treatment resistance to one or more adequate antidepressant trials, resulting in a disproportionately high burden of illness. Ketamine is a non-barbiturate, rapid-acting general anesthetic that has been increasingly studied in treatment resistant depression (TRD), typically at sub-anesthetic doses (0.5 mg/kg over 40 min by intravenous infusion). More...